149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)
Titel:
149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)
Auteur:
Munoz Couselo, E. Hughes, B.G.M. Bratland, Å. Gutzmer, R. Roshdy, O. González Mendoza, R. Schachter, J. Arance Fernandez, A.M. Grange, F. Meyer, N. Joshi, A.J. Billan, S. Grob, J.J. Zhang, P. Gumuscu, B. Swaby, R. Mortier, L.